Grünenthal Challenge: Repurposing Drugs for Pain Treatment

We feel pain when an injury or insult has occurred in the body. Pharmaceutical options for pain management range from over the counter treatments to prescription medications, however, individuals may experience different levels of pain relief when following the same treatment regimen. Therefore, the Seeker is looking to repurpose drugs not currently approved to treat pain for the successful treatment of pain.  

This Theoretical Challenge requires only a written proposal.

The feeling of pain can merely be a nuisance, but with increasing severity, it can become significantly debilitating. Sufferers of chronic pain experience mood changes that contribute to their inability to perform everyday tasks. Inadequate pain management has a detrimental effect on a person’s quality of life. Therefore, the Seeker is searching for novel solutions that identify repurposing opportunities for drugs not currently approved to treat pain.

This is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker.

To receive an award, the Solvers will have to transfer their exclusive intellectual property (IP) rights to the Seeker.

Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on August 20, 2018. 

Late submissions will not be considered.

ABOUT THE SEEKER

The Grünenthal Group: http://www.grunenthal.com/ 

The Grünenthal Group is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout and inflammation.

We are a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients. By sustainably investing in our research and development (R&D) above the industrial average, we are strongly committed to innovation.

In Grünenthal Innovation, we are strongly driven to seek new solutions for patients with severe diseases and high unserved medical need – and make these solutions accessible to patients. We combine an entrepreneurial spirit and our best-in-class science & technology approaches with excellence in execution.

With our fully integrated R&D and networked approach we combine the best of two worlds: we discover and develop new chemical entities (NCEs) and new technology platforms in-house. At the same time, we access external innovation and knowledge – and are courageous to exploit new paths.

Innovation is more than just the identification and development of a NCE. We believe innovation involves the combination of approaches including identifying new/different drug modalities, technologies and ways to optimize data handling to bring new therapies to patients.